Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4-CMS

NCT07746089 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07746089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07746089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4-CMS
Lead sponsor
argenx
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2030
Enrollment
105 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cms, congenital myasthenic syndrome